|
市場調查報告書
蛋白療法市場（抗凝血酵素、細胞激素、成長荷爾蒙、造血劑、胰島素、單細胞繁殖抗體、血漿蛋白、疫苗、其他治療）
Protein Therapeutics: Monoclonal Antibodies, Plasma Proteins, Vaccines, and Other Treatments, Global Market
|
蛋白療法市場（抗凝血酵素、細胞激素、成長荷爾蒙、造血劑、胰島素、單細胞繁殖抗體、血漿蛋白、疫苗、其他治療） 是由出版商Kalorama Information在2008年12月所出版的。
這份英文市場調查報告書包含250 pages 價格從美金3495起跳。
此報告書記載了蛋白療法市場的規模與成長率、開發動向與競爭、業界結構與未來變革等。報告書之內容摘要如下所示。
第1章 摘要
第2章 縮氨酸、蛋白質、酵素、抗體
- 縮氨酸
- 速積縮氨酸
- 血管活性腸道縮氨酸
- 胰臟氨基化合物相關縮氨酸
- 類鴉片縮氨酸
- 降血鈣素縮氨酸
- 其他
- 蛋白質
- 酵素
- 輔酶
- 抗體
- 同種異型
第3章 蛋白療法臨床上的應用
- 蛋白療法的優點
- 第1群：酵素與調整蛋白質
- 第2群：標的蛋白質
- 第3群
- 未來前景
第4章 市場分析
- 成長率
- 預測
- 各產品等級動向
- 疫苗市場預測
- 抗凝血酵素市場預測
- 造血劑市場預測
- 胰島素市場預測
- 成長荷爾蒙市場預測
- 血漿蛋白質市場預測
- 各產品等級動向
- 生產線
第5章 企業概要
第6章 結論與戰略性影響
附錄：用語
Abstract
The substances utilized for what is commonly referred to as ' protein
therapeutics' have one thing in common --- they are all composed primarily of
a-amino acids; and these a-amino acids are linked together by a distinct
chemical bond known as a "peptide" bond. Used in a variety of areas of
medicine, they are among the most interesting pharmaceutical markets.
Above-Average Growth Rate
What makes protein therapeutics interesting? The market for protein-based
therapeutics is one that is significant in its size and growing at a rate that
is well above what one would call "average" for the
therapeutics/pharmaceuticals industry. This makes them a continual topic of
interest for researchers examining the pharmaceutical markets.
The substances detailed in this report include:
- AntiThrombins
- Cytokines
- Growth Hormones
- Hematopoietics
- Insulin
- Monoclonal Antibodies
- Plasma Proteins
- Vaccines
- Miscellaneous
For each of these categories, market forecasts to 2012 are provided.
A Thriving Field with Abundant Competition
At the present time, there are at least 213 companies active in various
aspects of protein-based therapeutics development. This is at, or greater
than, the saturation level for the industry at this time. Presently, the
industry is at equilibrium --- companies at the lower end leaving and entering
at about the same rate and a small number of protein-based therapeutics
companies being acquired by the more-established participants.
This Kalorama Report Answers Key Questions about the Makret
Dr. Kenneth Krul, PhD has surveyed the marketplace and in this volume reviews
the key findings and conclusions about the current state of protein
therapeutics. The report features forecasts for the main groups of protein
therapeutics. Among the questions answered in this report:
- How large is the market; how fast is the market growing; and is such
growth sustainable?
- What does the pipeline of products that are expected to sustain this
growth look like?
- To what extent is the growth in this market dependent on production
introduction versus price-point for these products?
- Is the development pipeline filled with similar products or direct
alternatives such that product competition will be strong enough to
significantly affect price-point?
- What is the industry structure like? What changes can be expected in the
structure of the industry and how will these changes affect market size and
growth?
Table of Contents
TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
- Scope and Methodology
- Market Analysis
- Trends and Considerations
CHAPTER TWO: PEPTIDES, PROTEINS, ENZYMES AND ANTIBODIES
- Peptides
- Tachykinin Peptides
- Vasoactive Intestinal Peptides
- Pancreatic Polypeptide-Related Peptides
- Opioid Peptides
- Calcitonin Peptides
- Other Peptides
- Proteins
- Enzymes
- Coenzymes
- Antibodies
- Allotype
CHAPTER THREE: CLINICAL APPLICATIONS OF APPLICATIONS OF PROTEIN-BASED THERAPEUTICS
- Advantages of Protein Therapeutics
- Group I: Enzymes and Regulatory Proteins
- Group II: Targeted Proteins
- Group III:
- Toward the Future
CHAPTER FOUR: MARKET ANALYSIS
- Growth Rate
- Forecast
- Trending By Product Class
- Vaccines Market Forecast
- Antithrobins Market Forecast
- Hematopoietics Market Forecast
- Insulin Market Forecast
- Growth Hormones Market Forecast
- Plasma Proteins Market Forecast
- Trending by Product Class
- Pipeline
CHAPTER FIVE: COMPANY SNAPSHOTS
- Agennix
- Altus Pharmaceuticals
- Amgen
- Amylin Pharmaceuticals
- Biogen IDEC
- BioMarin Pharmaceutical, Inc.
- Cell Genesys, Inc
- Eli Lilly & Company
- Genentech, Inc.
- Genzyme Corporation
- Human Genome Sciences
- Medarex
- Neose Technologies, Inc.
- Novo Nordisk, Inc (USA)
- Regeneron Pharmaceuticals, Inc.
- Xoma, Ltd.
CHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS
- First Conclusion
- Second Conclusion
- Third Conclusion
- Fourth Conclusion
- Fifth Conclusion
- Sixth Conclusion
- Seventh Conclusion
- Eighth Conclusion
- Ninth Conclusion
- Tenth Conclusion
APPENDIX A: GLOSSARY
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: Estimated Global Market for Protein-Based Therapeutics by Major
Product Class: 2008 - 2018
- Figure 1-1: Trending in the Global Market for Protein-Based Therapeutics:
2008 - 2018
- Figure 1-2: Trending in the Protein-Based Therapeutics Global Market by
Product Class: 2008 - 2018
CHAPTER TWO: PEPTIDES, PROTEINS, ENZYMES AND ANTIBODIES
- Table 2-1: The Naturally Occurring Amino Acids
- Table 2-2: Significant Peptides in Biological Functions
- Table 2-3: Key Features of Immunoglobulin Isotypes
- Table 2-4: Immunoglobulin Functional Properties
CHAPTER THREE: CLINICAL APPLICATIONS OF APPLICATIONS OF PROTEIN-BASED THERAPEUTICS
- Table 3-1: Replacement Protein Therapeutics: Subgroup Ia
- Table 3-2: Augmenting Protein Therapeutics: Subgroup Ib
- Table 3-3: Protein Therapeutics with a Novel Function Activity: Subgroup Ic
- Table 3-4: Protein Vaccines: Subgroup IIa
- Table 3-5: Drug Delivery Protein Therapeutics: Subgroup IIb
- Table 3-6: Protein Vaccines: Group III
- Figure 3-1: Biotechnology-Based Therapeutics in Development by Product
Category: 2008 (Growth Factors, Interferons, Interleukins, Monoclonal
Antibodies (mAbs), Recombinant Hormones/Proteins, Vaccines, Others)
- Figure 3-2: Biotechnology-Based Therapeutics in Development by Protein and
Non-Protein Category: 2008
- Figure 3-3: Biotechnology-Based Therapeutics in Development by Clinical
Application (Disease State): 2008
- Table 3-7: Protein-Based Therapeutics in Development: 2008
- Figure 3-4: Distribution of Protein-Based Therapeutics in Development by
Orphan and Non-Orphan Drug Categories: 2008
- Figure 3-5: Distribution of Protein-Based Therapeutics in Development
Type: 2008
- Figure 3-6: Distribution of Protein-Based Vaccines in Development by
Recombinant and Non-Recombinant Categories: 2008
CHAPTER FOUR: MARKET ANALYSIS
- Table 4-1: Estimated Global Market for Protein-Based Therapeutics by Major
Product Class: 2008 - 2018
- Figure 4-1 : Trending in the Global Market for Protein-Based Therapeutics:
2008 - 2018
- Figure 4-2: Trending in the Protein-Based Therapeutics Global Market by
Product Class: 2008 - 2018
- Figure 4-3: Trending in the Protein-Based Therapeutics Global Market by
Product Class: 2008 - 2018
- Figure 4-4: Biopharmaceutical Approvals by the United States FDA: 1988 -
2007
- Table 4-2: Biopharmaceuticals Approved by the FDA: 2006 - 2008
- Table 4-3: Global Markets for Cytokines, Vaccines and Hematopoietic
Factors: 2008 - 2018
- Table 4-4: Companies Engaged in Protein-Based Therapeutics Development
|
